Associate Director, Site Alliances and Strategy at Summit Therapeutics

Job description

About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland. Overview of Role: The Associate Director, Site Alliances and Strategy is responsible for developing and maintaining strategic relationships with select clinical trial sites, site networks, and emerging clinical research partners, while contributing to broader Clinical Operations strategy and operational improvement initiatives. This role supports high-quality trial execution, portfolio scalability, and organizational effectiveness by connecting site insights with internal planning, process optimization, performance management, and change implementation. The position serves as a key interface across external sites and internal cross-functional stakeholders, ensuring site engagement and operational strategies align with portfolio priorities, business needs, and inspection-ready trial conduct. The ideal candidate thrives in a fast-paced, entrepreneurial environment, brings strong clinical trial operations experience, and has a demonstrated ability to build trusted external relationships, influence across matrixed teams, and translate site insights into strategies that reduce burden, improve enrollment, and strengthen long-term sponsor-site partnerships. Role and Responsibilities: Develops and executes site alliance strategies; Building and maintaining strong strategic relationships with key clinical institutions, investigators, research staff, and site leadership to strengthen sponsor-site collaboration Leads start-up optimization with internal and external site Study Start-Up teams, driving faster, simpler execution through early engagement, MSAs, standardized budgets and contracts, and streamlined processes. Serves as a primary Clinical Operations interface and escalation point for site alliance matters, partnering with study teams, CROs, vendors, and functional leaders to resolve operational issues, reduce site burden, and identify opportunities to improve external partner performance and value. Partners with cross-functional stakeholders, including Clinical Operations, Medical Affairs, Clinical Science, Regula